Male Breast Cancer Predisposition Factor: Create a Control Group

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center interventional study enrolling 120 male participants who are relatives of patients with pathogenic breast cancer gene variants. Participants have no personal cancer history and have undergone an oncogenetic consultation; a blood sample will be analyzed and a questionnaire completed. The goal is to collect and describe genetic, environmental, and psychosocial data to understand predisposition factors. Interventions include questionnaire completion and whole exome sequencing. Results may help clarify inherited risk patterns and inform future research in male breast cancer predisposition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. A male volunteer participant with no personal history of cancer, registered in the IUCT-O oncogenetics database as a relative of a patient carrying a pathogenic or likely pathogenic variant in one of the cancer predisposition genes routinely analyzed at the oncogenetics laboratory
* 2\. Age ≥ 66 years
* 3\. Participant with no known family relationship to a patient of the MATADOR1 cohort
* 4\. Participant who has undergone an oncogenetic consultation at the IUCT-O
* 5\. Participant who does not carry the familial mutation in any of the cancer predisposition genes previously tested
* 6\. Participant for which an archived blood sample is available for the research in the oncogenetics laboratory
* 7\. Participant having signed an informed consent form before inclusion in the study and before any study specific procedure

Exclusion Criteria:

* 1\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Where it's running

• Institut Universitaire du Cancer Toulouse - Oncopole, Laboratoire d'oncogénétique
  Toulouse, France Recruiting

Study contacts

• Study coordinator: Ayman AL SAATI, PharmD, PhD
• Email: alsaati.ayman@iuct-oncopole.fr
• Phone: 0033 5 31 15 52 42

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for male breast cancer using endocrine therapy

  This study is testing different combinations of hormone therapy for men with early to mid-stage breast cancer to see which one works best compared to the usual treatment.

  Recruiting at 9 sites Phase 2 Dana-Farber Cancer Institute · Washington D.C., District of Columbia and 8 other locations · NCT05501704

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• Biomarkers and immune responses in early-stage solid cancers treated with immunotherapy

  This study tests immune biomarkers in patients with early-stage solid cancers who are receiving immune checkpoint blockade before surgery.

  Recruiting Institut Claudius Regaud · Toulouse and 2 other locations · NCT07427186

• Atlas of cell organelles and protein patterns in breast cancer subtypes

  This project will collect tumor and blood samples from people with early or newly metastatic breast cancer to test how much fat accumulates in tiny cell structures (lipid droplets) and to map protein patterns across tumor subtypes.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07233928

• Comparing blood levels of the free‑DXd payload from trastuzumab‑deruxtecan by BMI in people with advanced or metastatic breast cancer

  This study will test whether body mass index changes blood levels of the free‑DXd payload in adults with locally advanced or metastatic HER2‑low or HER2‑positive breast cancer who are receiving trastuzumab‑deruxtecan.

  Recruiting at 6 sites Phase 4 Institut Claudius Regaud · Angers and 9 other locations · NCT07195344

• Detecting double-positive (tumor marker/CD45+) cells in the blood of people with metastatic cancer

  This one-day study will test two blood-based methods to find double-positive tumor/CD45+ circulating cells in adults who are about to start treatment for various metastatic cancers.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06967961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.